We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Issues Guidance on Consolidating ANDAs Amid Generic Backlog
The item has been added to your shopping cart.
CDER Issues Guidance on Consolidating ANDAs Amid Generic Backlog
In an effort to ease a major generics approval backlog, the FDA is advising generic drugmakers and regulators on how best to streamline ANDAs of varying strengths into a single application.